United States v. Generix Drug Corp.
Headline: Court rules FDA approval can be required for whole generic drug products, not just active ingredients, making it harder for distributors to market generics with different inactive ingredients.
Holding: A generic drug product is a 'drug' under the Act and can be a 'new drug' requiring FDA approval until the finished product no longer falls within §201(p).
- Distributors may need FDA approval for certain generic formulations.
- Generic makers face higher compliance costs if inactive ingredients differ.
- FDA gains clearer authority to regulate finished drug products.
Summary
Background
Generix is a distributor of copycat prescription drugs that contain the same active ingredients as brand-name products but may use different inactive ingredients, called excipients. The Government sued to stop Generix from selling several generic products that the FDA had never approved. The District Court found a reasonable possibility that differences in excipients could make six of Generix's products less safe or effective and enjoined their sale. The Court of Appeals reversed, saying only the active ingredient counts and vacated the injunction. The Supreme Court took the case because circuits had disagreed.
Reasoning
The Court addressed whether the statutory word 'drug' means only an active ingredient or the whole finished product. It examined the Act's definition and related provisions requiring labels and applications to list all components, and concluded that Congress intended 'drug' to include the entire product - active and inactive ingredients. The Court rejected arguments based on some legislative history and past FDA practice as insufficient to limit the statute's plain meaning. The Court did not decide whether two products that are proved bioequivalent despite different excipients would always be the same 'drug.'
Real world impact
As a result, generic products can be 'new drugs' requiring FDA approval until they no longer meet the statute's definition. Distributors and manufacturers that sell formulations with different inactive ingredients may need to submit applications or face enforcement. The ruling leaves some uncertainty about proven bioequivalence and how the FDA will apply these principles in future cases. The decision affects national drug marketing rules.
Ask about this case
Ask questions about the entire case, including all opinions (majority, concurrences, dissents).
What was the Court's main decision and reasoning?
How did the dissenting opinions differ from the majority?
What are the practical implications of this ruling?